Top 5 Stock Picks of Eli Casdin’s Casdin Capital

4. Fate Therapeutics, Inc. (NASDAQ:FATE)

Casdin Capital’s Stake Value: $131,818,000
Percentage of Casdin Capital’s Portfolio: 5.91%
Number of Hedge Fund Holders: 31

Fate Therapeutics, Inc. (NASDAQ:FATE) is a bio-pharmaceutical start-up working on cutting-edge cellular immunotherapies for cancer patients. By the end of the first quarter of 2022, Insider Monkey identified 31 hedge funds long Fate Therapeutics, Inc. (NASDAQ:FATE). The total value of these funds was over $1.26 billion.

Jeremy Green of Redmile Group is the lead stakeholder of Fate Therapeutics, Inc. (NASDAQ:FATE). The fund owns more than 12.96 million shares of the company, worth $502.35 million. Next on the list is Catherine D. Wood’s ARK Investment Management, which owns 10.99 million company shares worth over $426.01 million.

On July 11, Etzer Darout of BMO Capital raised Fate Therapeutics, Inc. (NASDAQ:FATE) from ‘Market Perform’ to ‘Outperform’ with a $47 price objective, down from $50. Given its universal, off-the-shelf products, the company’s iPSC platform is ideally positioned in the cell therapy market, the analyst informed investors in a research note.

Casdin Capital started building its position in Fate Therapeutics, Inc. (NASDAQ:FATE) during the second quarter of 2017, purchasing shares worth over $1.78 million. At the end of Q1 2022, the hedge fund owned 3.40 million Fate Therapeutics, Inc. (NASDAQ:FATE) shares, valued at over $131.82 million. The company represented 5.91% of the hedge fund’s portfolio.